Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 19;8(5):750-757.
doi: 10.1002/mdc3.13228. eCollection 2021 Jul.

Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review

Iro Boura  1   2 , Nikolaos Haliasos  3   4 , Ιrene-Areti Giannopoulou  1   2 , Dimitrios Karabetsos  3 , Cleanthe Spanaki  1   2
Affiliations
Review

Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review

Iro Boura et al. Mov Disord Clin Pract. .

Abstract

Background: Deep brain stimulation (DBS), levodopa-carbidopa intestinal gel (LCIG) and subcutaneous apomorphine infusion are device-aided therapies (DATs) for advanced Parkinson's disease (PD). We present a case series from the Cretan PD Registry who required 2 DATs for optimal management along with a systematic review of similar studies.

Cases: From 2009 to 2020, we retrospectively studied all PD patients who were simultaneously treated with 2 DATs. Six patients on DBS required an infusion treatment for persisting or re-emergent fluctuations because of disease progression. Two patients on LCIG infusion received DBS as a levodopa-sparing strategy because of drug-induced complications. Fluctuations and quality of life improved in all patients.

Literature review: We identified 4 case series, 1 prospective and 1 retrospective study that included a total of 50 DBS-treated patients who required an infusion therapy. Improvement in motor outcomes, assessed in different ways, was a constant finding.

Conclusions: Selected PD patients on 1 DAT may experience additional benefit from a second DAT, for several reasons along the course of their disease. Although infusion therapies optimize dopaminergic drug delivery in fluctuating DBS-treated patients, DBS added on LCIG treatment has an additive symptomatic effect that allows levodopa dose reduction in patients with drug-induced side effects.

Keywords: Parkinson's disease; deep brain stimulation; infusion pump.

PubMed Disclaimer

Conflict of interest statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not‐for‐profit sectors. There are no conflicts of interest or financial disclosures to report.

Figures

FIG. 1
FIG. 1
(A) Patients' therapies timelines. (B) Axial images obtained from post‐operative MRI scans at the level of the sub‐thalamic nucleus showing the DBS leads positions for patients 1, 2, 5, 6, 7, and 8 (DBS, deep brain stimulation; LCIG, levodopa carbidopa intestinal gel; SCAI, subcutaneous apomorphine infusion).
See this image and copyright information in PMC

References

    1. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 2018;33(8):1248–1266. - PubMed
    1. Timpka J, Nitu B, Datieva V, Odin P, Antonini A. Device‐Aided Treatment Strategies in Advanced Parkinson's Disease. Int Rev Neurobiol 2017;132:453–474. - PubMed
    1. Wider C, Pollo C, Bloch J, Burkhard PR, Vingerhoets FJ. Long‐term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord 2008;14(2):114–119. - PubMed
    1. Buongiorno M, Antonelli F, Cámara A, et al. Long‐term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord 2015;21(8):871–876. - PubMed
    1. Valldeoriola F, Grandas F, Santos‐García D, et al. Long‐term effectiveness of levodopa‐carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease. Neurodegener Dis Manag 2016;6(4):289–298. - PubMed

LinkOut - more resources